Abstract
Background and Objective: Glabridin (Glab) is a polyphenolic flavonoid of licorice acclaimed for its skin whitening properties. However, its poor solubility, low physicochemical stability and inefficient percutaneous penetration create hurdles in the best use of this agent in dermocosmetic application. The purpose of the present work was to prepare and evaluate Glabridinloaded nanostructured lipid carrier (Glab NLC) in order to enhance its skin permeation, and hence, promote its skin-whitening potential in cosmetic formulations. Nanostructured lipid carrier (NLC) has already proven its potential for drug delivery via the skin by offering various benefits, like high tolerability, biocompatibility, high drug loading, improved stability, and close contact with stratum corneum, leading to rich skin penetration and protection of bioactive from degradation.
Methods: NLC was prepared by solvent emulsification diffusion technique and was evaluated for particle size, zeta potential, polydispersity index, drug loading and encapsulation, and in vitro drug release. Optimized formulation was incorporated into a cream base, and its skin whitening activity was evaluated. Glycerol monostearate (GMS) and olive oil were chosen as solid and liquid lipids for NLC formulation.
Results: The particle size, PDI, zeta potential, entrapment efficiency, and drug release of optimized formulation were found to be 189 nm, 0.259, -14.5mV, 94.56 %, and 98.86 ± 0.80 %, respectively. The optimized NLC was incorporated into a suitable cream base and evaluated. The skin whitening activity of Glabridin NLC cream was determined by performing tyrosinase inhibition activity. The percentage inhibition value of GlabNLC loaded cream and Kojic acid against mushroom tyrosinase was found to be 60.31% and 52.61%, respectively.
Conclusion: The obtained results advocate lipid particles as an appropriate carrier of Glabridin for skin whitening cosmetic cream.
Keywords: Glabridin, nanostructured lipid carrier, cream, skin whitening, tyrosinase inhibition, melanin, mushroom tyrosinase.
Graphical Abstract
[1]
Ribeiro, L.N.; Franz-Montan, M.; Breitkreitz, M.C.; Alcântara, A.C.; Castro, S.R.; Guilherme, V.A.; Barbosa, R.M.; de Paula, E. Nanostruc-tured lipid carriers as robust systems for topical lidocaine-prilocaine release in dentistry. Eur. J. Pharm. Sci., 2016, 93, 192-202.
[http://dx.doi.org/10.1016/j.ejps.2016.08.030] [PMID: 27543066]
[http://dx.doi.org/10.1016/j.ejps.2016.08.030] [PMID: 27543066]
[2]
Puglia, C.; Bonina, F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv., 2012, 9(4), 429-441.
[http://dx.doi.org/10.1517/17425247.2012.666967] [PMID: 22394125]
[http://dx.doi.org/10.1517/17425247.2012.666967] [PMID: 22394125]
[3]
Shah, R.; Eldridge, D.; Palombo, E.; Harding, I. Lipid nanoparticles: Production, characterization and stability; Springer: London, 2015, pp. 18-19.
[http://dx.doi.org/10.1007/978-3-319-10711-0_2]
[http://dx.doi.org/10.1007/978-3-319-10711-0_2]
[4]
Shah, K.A.; Date, A.A.; Joshi, M.D.; Patravale, V.B. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int. J. Pharm., 2007, 345(1-2), 163-171.
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.061] [PMID: 17644288]
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.061] [PMID: 17644288]
[5]
Souto, E.B.; Müller, R.H. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int. J. Cosmet. Sci., 2008, 30(3), 157-165.
[http://dx.doi.org/10.1111/j.1468-2494.2008.00433.x] [PMID: 18452432]
[http://dx.doi.org/10.1111/j.1468-2494.2008.00433.x] [PMID: 18452432]
[6]
Wissing, S.; Lippacher, A.; Müller, R. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J. Cosmet. Sci., 2001, 52(5), 313-324.
[PMID: 11567210]
[PMID: 11567210]
[7]
Pardeike, J.; Hommoss, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366(1-2), 170-184.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
[8]
] Bethesda (MD): National library of medicine (US), national center for biotechnology information , 2004. Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/Glabridin (Accessed on 2022 Jan. 5).
[9]
Simmler, C.; Pauli, G.F.; Chen, S.N. Phytochemistry and biological properties of glabridin. Fitoterapia, 2013, 90, 160-184.
[http://dx.doi.org/10.1016/j.fitote.2013.07.003] [PMID: 23850540]
[http://dx.doi.org/10.1016/j.fitote.2013.07.003] [PMID: 23850540]
[10]
Licorice extract., Available from:
https://www.lorealparisusa.com/ingredient-library/licorice-extract.aspx(Accessed on December 12, 2021).
[11]
Wang, W.P.; Hul, J.; Sui, H.; Zhao, Y.S.; Feng, J.; Liu, C. Glabridin nanosuspension for enhanced skin penetration: Formulation optimization, in vitro and in vivo evaluation. Pharmazie, 2016, 71(5), 252-257.
[PMID: 27348968]
[PMID: 27348968]
[12]
Obagi, U.; Gandhi, R.K. Skin rejuvenation and resurfacing. Maxillofacial Surgery, 3rd ed; Brennan, P.A.; Schliephake, H.; Ghali, G.E.; Cascarini, L., Eds.; Churchill Livingstone, ; , 2017, pp. 1286-1301.
[http://dx.doi.org/10.1016/B978-0-7020-6056-4.00085-X]
[http://dx.doi.org/10.1016/B978-0-7020-6056-4.00085-X]
[13]
Hespeler, D.; Kaltenbach, J.; Pyo, S.M. Glabridin smart Pearls-Silica selection, production, amorphous stability and enhanced solubility. Int. J. Pharm., 2019, 561, 228-235.
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.028] [PMID: 30836152]
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.028] [PMID: 30836152]
[14]
Ao, M.; Shi, Y.; Cui, Y.; Guo, W.; Wang, J.; Yu, L. Factors influencing glabridin stability. Nat. Prod. Commun., 2010, 5(12), 1907-1912.
[http://dx.doi.org/10.1177/1934578X1000501214] [PMID: 21299118]
[http://dx.doi.org/10.1177/1934578X1000501214] [PMID: 21299118]
[15]
Park, Y.S.; Park, H.J.; Lee, J. Stabilization of glabridin by chitosan nano-complex. J. Korean Soc. Appl. Biol. Chem., 2012, 55(4), 457-462.
[http://dx.doi.org/10.1007/s13765-012-2001-0]
[http://dx.doi.org/10.1007/s13765-012-2001-0]
[16]
Yasir, M.; Sara, U.V. Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evalua-tion. Acta Pharm. Sin. B, 2014, 4(6), 454-463.
[http://dx.doi.org/10.1016/j.apsb.2014.10.005] [PMID: 26579417]
[http://dx.doi.org/10.1016/j.apsb.2014.10.005] [PMID: 26579417]
[17]
Cirri, M.; Maestrini, L.; Maestrelli, F.; Mennini, N.; Mura, P.; Ghelardini, C.; Di Cesare Mannelli, L. Design, characterization and in vivo eval-uation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy. Drug Deliv., 2018, 25(1), 1910-1921.
[http://dx.doi.org/10.1080/10717544.2018.1529209] [PMID: 30451015]
[http://dx.doi.org/10.1080/10717544.2018.1529209] [PMID: 30451015]
[18]
Trotta, M.; Debernardi, F.; Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm., 2003, 257, 153-160.
[http://dx.doi.org/10.1016/S0378-5173(03)00135-2]
[http://dx.doi.org/10.1016/S0378-5173(03)00135-2]
[19]
Singh, A.P.; Sharma, S.K.; Gaur, P.K.; Gupta, D.K. Fabrication of mupirocin-loaded nanostructured lipid carrier and its in-vitro characteriza-tion. Assay Drug Dev. Technol., 2021, 19(4), 216-225.
[http://dx.doi.org/10.1089/adt.2020.1070] [PMID: 33781090]
[http://dx.doi.org/10.1089/adt.2020.1070] [PMID: 33781090]
[20]
Gupta, N.; Dubey, A.; Prasad, P.; Roy, A. Formulation and evaluation of herbal fairness cream comprising hydroalcoholic extracts of pleuro-tusostreatus, Glycyrrhizaglabra and Camellia sinensis. UK J. Pharm. Biosc., 2015, 3(3), 40-45.
[http://dx.doi.org/10.20510/ukjpb/3/i3/89410]
[http://dx.doi.org/10.20510/ukjpb/3/i3/89410]
[21]
Alobaidi, A.H.; Hamad, E.S.; Kudair, K.A.; Alsamarai, A.M. Formulation of hypopigmentation cream and evaluation of its effect on skin pigment. Part I: Formulation of the Product. Nasza Dermatol. Online, 2014, 5(1), 9-13.
[http://dx.doi.org/10.7241/ourd.20141.02]
[http://dx.doi.org/10.7241/ourd.20141.02]
[22]
Maru, A.D.; Lahoti, S.R. Formulation and evaluation of moisturizing cream containing sunflower wax. Int. J. Pharm. Pharm. Sci., 2018, 10(11), 54-59.
[http://dx.doi.org/10.22159/ijpps.2018v10i11.28645]
[http://dx.doi.org/10.22159/ijpps.2018v10i11.28645]
[23]
Chen, J.; Yu, X.; Huang, Y. Inhibitory mechanisms of glabridin on tyrosinase. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2016, 168, 111-117.
[http://dx.doi.org/10.1016/j.saa.2016.06.008] [PMID: 27288962]
[http://dx.doi.org/10.1016/j.saa.2016.06.008] [PMID: 27288962]
[24]
Choi, S.Y.; Kim, S.; Kim, H.; Suk, K.; Hwang, J.S.; Lee, B.G.; Kim, A.J.; Kim, S.Y. (4-Methoxy-benzylidene)-(3-methoxy-phenyl)-amine, a nitrogen analog of stilbene as a potent inhibitor of melanin production. Chem. Pharm. Bull. (Tokyo), 2002, 50(4), 450-452.
[http://dx.doi.org/10.1248/cpb.50.450] [PMID: 11963989]
[http://dx.doi.org/10.1248/cpb.50.450] [PMID: 11963989]
[25]
Choe-sinsik, R. Glabridin-Zein complex nanoparticle, manufacturing method thereof and use thereof.South Korea Patent, KR101902846B1, 2017.
[26]
Gaba, B.; Fazil, M.; Khan, S.; Ali, A.; Baboota, S.; Ali, J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull. Fac. Pharm. Cairo Univ., 2015, 53(2), 147-159.
[http://dx.doi.org/10.1016/j.bfopcu.2015.10.001]
[http://dx.doi.org/10.1016/j.bfopcu.2015.10.001]
[27]
Patel, K.; Padhye, S.; Nagarsenker, M. Duloxetine HCl lipid nanoparticles: Preparation, characterization, and dosage form design. AAPS PharmSciTech, 2012, 13(1), 125-133.
[http://dx.doi.org/10.1208/s12249-011-9727-6] [PMID: 22167415]
[http://dx.doi.org/10.1208/s12249-011-9727-6] [PMID: 22167415]
[28]
Witayaudom, P.; Klinkesorn, U. Effect of surfactant concentration and solidification temperature on the characteristics and stability of nanostructured lipid carrier (NLC) prepared from rambutan (Nephelium lappaceum L.) kernel fat. J. Colloid Interface Sci., 2017, 505, 1082-1092.
[http://dx.doi.org/10.1016/j.jcis.2017.07.008] [PMID: 28697547]
[http://dx.doi.org/10.1016/j.jcis.2017.07.008] [PMID: 28697547]
[29]
Gonzalez-Mira, E.; Egea, M.A.; Souto, E.B.; Calpena, A.C.; García, M.L. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology, 2011, 22(4), 045101.
[http://dx.doi.org/10.1088/0957-4484/22/4/045101] [PMID: 21169662]
[http://dx.doi.org/10.1088/0957-4484/22/4/045101] [PMID: 21169662]
[30]
Chaitali, J.; Vaishali, K.; Santosh, P. Formulation and evaluation of antifungal non-aqueous microemulsion for topical drug delivery of grise-ofulvin. Inventi Impact: Pharm Tech, 2015, 2015, 38-50.
[31]
Mohammadi, M.; Assadpour, E.; Jafari, S.M. Encapsulation of food ingredients by nanostructured lipid carriers (NLCs). Nanoencapsulation in the food industry, Lipid-based nanostructures for food encapsulation purposes; Jafari, S.M., Ed.; Academic Press, 2019, pp. 217-270.
[http://dx.doi.org/10.1016/B978-0-12-815673-5.00007-6]
[http://dx.doi.org/10.1016/B978-0-12-815673-5.00007-6]
[32]
Han, F.; Li, S.; Yin, R.; Liu, H.; Xu, L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf. A Physicochem. Eng., 2008, 315, 210-216.
[33]
Khosa, A.; Reddi, S.; Saha, R.N. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother., 2018, 103, 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[34]
Kandadi, P.; Syed, M.A.; Surender, G.; Veerabrahma, K. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm. Sin. B, 2013, 3(5), 345-353.
[http://dx.doi.org/10.1016/j.apsb.2013.08.001]
[http://dx.doi.org/10.1016/j.apsb.2013.08.001]
[35]
Nighojkar, P.A.; Devi, S.K.U.; Pund, K.V.; Gadakh, R.T.; Shinde, M.G. Formulation development of BMP-NLC enriched gel. Int. J. Pharm. Sci. Res., 2012, 3(9), 3522-3529.
[36]
Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm., 2010, 67(3), 217-223.
[PMID: 20524422]
[PMID: 20524422]
[37]
Negi, L.M.; Jaggi, M.; Talegaonkar, S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int. J. Pharm., 2014, 461(1-2), 403-410.
[http://dx.doi.org/10.1016/j.ijpharm.2013.12.006] [PMID: 24345574]
[http://dx.doi.org/10.1016/j.ijpharm.2013.12.006] [PMID: 24345574]
[38]
Glabridin dosage in cosmetics, Available from:
http://varucosmotech. com/2019/10/22/how-is-it-used/ (Accessed on 12 December 2021).
[39]
Vanitha, M.; Soundhari, C. Isolation and characterisation of mushroom tyrosinase and screening of herbal extracts for anti-tyrosinase activi-ty. Int. J. Chemtech Res., 2017, 10, 1156-1167.
[40]
Tief, K.; Hahne, M.; Schmidt, A.; Beermann, F. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. Eur. J. Biochem., 1996, 241(1), 12-16.
[http://dx.doi.org/10.1111/j.1432-1033.1996.0012t.x] [PMID: 8898882]
[http://dx.doi.org/10.1111/j.1432-1033.1996.0012t.x] [PMID: 8898882]
[41]
Curto, E.V.; Kwong, C.; Hermersdörfer, H.; Glatt, H.; Santis, C.; Virador, V.; Hearing, V.J., Jr; Dooley, T.P. Inhibitors of mammalian melano-cyte tyrosinase: In vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Biochem. Pharmacol., 1999, 57(6), 663-672.
[http://dx.doi.org/10.1016/S0006-2952(98)00340-2] [PMID: 10037452]
[http://dx.doi.org/10.1016/S0006-2952(98)00340-2] [PMID: 10037452]
[42]
Matsuda,, H.; Higashino,, M.; Nakai,, Y.; Iinuma,, M.; Kubo,, M.; Lang,, F.A. Studies of cuticle drugs from natural sources. IV. Inhibitory effects of some Arctostaphylos plants on melanin biosynthesis. Biol. Pharm. Bul, 1996, 19(1), 153-156.
[http://dx.doi.org/10.1248/bpb.19.153] [PMID: 8820931]
[http://dx.doi.org/10.1248/bpb.19.153] [PMID: 8820931]
Related Books
The Vertebrate Pigmentary System: From Pigment Cells to Disorders
Article Metrics
1